Indaptus Therapeutics (NASDAQ:INDP) Stock Price Down 9.2%

Indaptus Therapeutics, Inc. (NASDAQ:INDP)’s share price dropped 9.2% on Monday . The company traded as low as $1.28 and last traded at $1.28. Approximately 20,816 shares changed hands during trading, a decline of 49% from the average daily volume of 40,734 shares. The stock had previously closed at $1.41.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Indaptus Therapeutics in a report on Monday, June 17th.

Indaptus Therapeutics Stock Performance

The stock has a fifty day simple moving average of $1.72 and a two-hundred day simple moving average of $2.11. The stock has a market capitalization of $10.93 million, a price-to-earnings ratio of -0.72 and a beta of 1.48.

Indaptus Therapeutics (NASDAQ:INDP) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. Research analysts forecast that Indaptus Therapeutics, Inc. will post -1.72 earnings per share for the current year.

Institutional Trading of Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC bought a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 14,232 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned 0.17% of Indaptus Therapeutics at the end of the most recent reporting period. Institutional investors own 7.06% of the company’s stock.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.